Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant combined with AG chemotherapy in metastatic pancreatic cancer
NCT07475234Phase 2Not yet recruiting
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of rimegepant in pancreatic adenocarcinoma (PDAC). Planned start Mar 2026; status: not yet recruiting.
02
Drugs
rimegepant
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07475234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07475234.